Infiniant Health is a microbiome company dedicated to developing the next generation of products to establish, restore, and maintain a healthy human gut microbiome.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
05/25/2021 | Series D-2 | $5.99MM | $xx.xx | $273.74MM | Acre Venture Partners, Bow Capital, Cargill, Horizons Ventures, Johnson & Johnson Innovation, Manna Tree Partners, Spruce Capital Partners | |
Price per Share
$xx.xx
Shares Outstanding
496,978
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Acre Venture Partners, Bow Capital, Cargill, Horizons Ventures, Johnson & Johnson Innovation, Manna Tree Partners, Spruce Capital Partners
|
||||||
05/25/2021 | Series D-1 | $60.45MM | $xx.xx | $273.74MM | Acre Venture Partners, Bow Capital, Cargill, Horizons Ventures, Johnson & Johnson Innovation, Manna Tree Partners, Spruce Capital Partners | |
Price per Share
$xx.xx
Shares Outstanding
4,512,952
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Acre Venture Partners, Bow Capital, Cargill, Horizons Ventures, Johnson & Johnson Innovation, Manna Tree Partners, Spruce Capital Partners
|
||||||
06/13/2018 | Series C | $40.83MM | $xx.xx | $131.99MM | Acre Venture Partners, Alta Partners, Arla Foods, Bill & Melinda Gates Foundation, Bow Capital, Continental Grain Company, Horizons Ventues, Johnson & Johnson Innovation, Spruce Capital Partners, Tate & Lyle Ventures | |
Price per Share
$xx.xx
Shares Outstanding
4,488,437
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Acre Venture Partners, Alta Partners, Arla Foods, Bill & Melinda Gates Foundation, Bow Capital, Continental Grain Company, Horizons Ventues, Johnson & Johnson Innovation, Spruce Capital Partners, Tate & Lyle Ventures
|
||||||
05/03/2017 | Series B | $20MM | $xx.xx | $51.07MM | Acre Venture Partners, Bow Capital, Horizons Ventures, Spruce Capital Partners, Tate & Lyle Ventures | |
Price per Share
$xx.xx
Shares Outstanding
3,577,364
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.3x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Acre Venture Partners, Bow Capital, Horizons Ventures, Spruce Capital Partners, Tate & Lyle Ventures
|
||||||
08/17/2015 | Series A | $8.44MM | $xx.xx | $22.72MM | Alta Partners, Horizons Ventures, Tate & Lyle Ventures | |
Price per Share
$xx.xx
Shares Outstanding
2,091,709
Liquidation Pref Order
4
Liquidation Pref As Multiplier
2.4x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Alta Partners, Horizons Ventures, Tate & Lyle Ventures
|
||||||
09/01/2014 | Series Seed | $960,755.00 | $xx.xx | $3.84MM | Tate & Lyle Ventures | |
Price per Share
$xx.xx
Shares Outstanding
725,098
Liquidation Pref Order
5
Liquidation Pref As Multiplier
1.6x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Tate & Lyle Ventures
|